Home › Urogenital Cancer › New York › New York City
Urogenital Cancer clinical trials in New York City, NY
3 studies for Urogenital Cancer are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RecruitingObservational study
- NYU Grossman School of Medicine, New York
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
RecruitingPhase 1
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Urogenital Cancer trials in other cities
- Washington, DC6 studies
- Houston, TX6 studies
- Columbus, OH5 studies
- Nashville, TN5 studies
- Durham, NC4 studies
- Ann Arbor, MI3 studies
- Atlanta, GA3 studies
- Cedar Rapids, IA3 studies
- St. Louis, MO3 studies
- Orange, CA3 studies
- Los Angeles, CA3 studies
- Omaha, NE3 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.